LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| BT-20 | PIK-93 | 0.37 | uM | LJP5 | 72 | hr | 1097 | 3878 | 3769 | 1.0288 | 1.0406 |
| MDA-MB-231 | PD173074 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 4648 | 4513 | 1.0298 | 1.0410 |
| MDA-MB-231 | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4648 | 4513 | 1.0299 | 1.0412 |
| SK-BR-3 | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4341 | 4223 | 1.0280 | 1.0419 |
| MCF7 | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 1209 | 4214 | 4093 | 1.0296 | 1.0421 |
| BT-20 | Nilotinib | 0.37 | uM | LJP5 | 72 | hr | 1097 | 3882 | 3769 | 1.0300 | 1.0423 |
| MDA-MB-231 | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 1235 | 4652 | 4513 | 1.0308 | 1.0424 |
| SK-BR-3 | Selumetinib | 0.37 | uM | LJP6 | 72 | hr | 1401 | 4343 | 4223 | 1.0286 | 1.0427 |
| MCF7 | Ruxolitinib | 0.37 | uM | LJP5 | 72 | hr | 1209 | 4219 | 4093 | 1.0309 | 1.0439 |
| MDA-MB-231 | Nintedanib | 0.12 | uM | LJP6 | 72 | hr | 1235 | 4658 | 4513 | 1.0321 | 1.0442 |
| MCF 10A | Withaferin A | 0.12 | uM | LJP5 | 72 | hr | 962 | 11032 | 10605 | 1.0403 | 1.0443 |
| MDA-MB-231 | Seliciclib | 0.04 | uM | LJP5 | 72 | hr | 1235 | 4659 | 4513 | 1.0323 | 1.0444 |
| MDA-MB-231 | PHA-665752 | 0.12 | uM | LJP5 | 72 | hr | 1235 | 4659 | 4513 | 1.0324 | 1.0446 |
| MDA-MB-231 | PD173074 | 0.04 | uM | LJP6 | 72 | hr | 1235 | 4661 | 4513 | 1.0327 | 1.0451 |
| MCF7 | Nilotinib | 0.04 | uM | LJP5 | 72 | hr | 1209 | 4224 | 4093 | 1.0321 | 1.0455 |
| SK-BR-3 | Ruxolitinib | 3.33 | uM | LJP5 | 72 | hr | 1401 | 4351 | 4223 | 1.0304 | 1.0456 |
| BT-20 | NVP-AEW541 | 3.33 | uM | LJP5 | 72 | hr | 1097 | 3891 | 3769 | 1.0323 | 1.0456 |
| SK-BR-3 | PLX-4720 | 0.12 | uM | LJP5 | 72 | hr | 1401 | 4352 | 4223 | 1.0305 | 1.0457 |
| SK-BR-3 | Sorafenib | 3.33 | uM | LJP6 | 72 | hr | 1401 | 4352 | 4223 | 1.0306 | 1.0458 |
| Hs 578T | XL147 | 0.04 | uM | LJP5 | 72 | hr | 658 | 3992 | 3846 | 1.0380 | 1.0459 |
| Hs 578T | CP466722 | 0.37 | uM | LJP5 | 72 | hr | 658 | 3992 | 3846 | 1.0381 | 1.0460 |
| BT-20 | SB590885 | 1.11 | uM | LJP5 | 72 | hr | 1097 | 3893 | 3769 | 1.0328 | 1.0463 |
| Hs 578T | NVP-AEW541 | 0.12 | uM | LJP5 | 72 | hr | 658 | 3994 | 3846 | 1.0385 | 1.0465 |
| BT-20 | PHA-665752 | 0.37 | uM | LJP5 | 72 | hr | 1097 | 3894 | 3769 | 1.0330 | 1.0466 |
| MDA-MB-231 | Linifanib | 0.37 | uM | LJP6 | 72 | hr | 1235 | 4667 | 4513 | 1.0340 | 1.0468 |